Understand the source comparison
Healing Peptides 2026 Update: Research Peptide Comparison
BPC-157 Promotes angiogenesis via VEGF upregulation; accelerates soft tissue repair through fibroblast activation Phase 3 human trial (Nature Medicine Jan 2026): 42% faster healing vs placebo in 72-week study 98.8% (HPLC + third-party MS verification) 18–22 da
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Promotes angiogenesis via VEGF upregulation; accelerates soft tissue repair through fibroblast activation
- Phase 3 human trial (Nature Medicine Jan 2026): 42% faster healing vs placebo in 72-week study
- 98.8% (HPLC + third-party MS verification)
- 18–22 days
- First-line consideration for tissue repair protocols. Human trial data now substantiates mechanism
- TB-500 (Thymosin Beta-4)
- Stimulates collagen deposition and actin upregulation in damaged tissue; enhances tendon/ligament healing
- Phase 2 trial (Lancet Rheumatology 2026): 68% structural improvement on MRI vs 31% control group at 16 weeks
- 98.5% (HPLC + third-party MS verification)
- 20–25 days
- Strong evidentiary basis for musculoskeletal research. MRI-confirmed outcomes reduce approval risk
- Thymalin
- Modulates thymulin secretion; restores T-cell differentiation in thymic involution (immunosenescence)
- Phase 2 ongoing (preliminary 40-patient cohort): measurable T-cell response at 10mg IM twice weekly
- 97.9% (HPLC + third-party MS verification)
- 22–28 days
- Emerging data for immune aging research. Trial results expected Q4 2026 will clarify dosing
- Cerebrolysin
- Neurotrophic peptide complex; supports BDNF expression and synaptic plasticity in neurodegeneration models
- Multiple Phase 3 trials in stroke/TBI (Europe); limited U.S. regulatory pathway; mechanistic validation strong
- 96.5–98% (varies by batch; complex peptide mixture harder to standardize)
- 25–30 days
- Neuroprotection research standard outside U.S.; regulatory complexity limits domestic use
- Dihexa
- Crosses blood-brain barrier; binds hepatocyte growth factor (HGF) receptor to promote synaptogenesis
- Preclinical only (rodent models); no Phase 1 human data as of 2026
- 99.1% (single synthetic peptide; easier purity control than mixtures)
- 18–20 days
- Promising mechanism but lacks human trial validation. Suitable for exploratory studies only